Drug intelligence / Profile preview

XTS002

Development stage: Preclinical
Lead developer: X-tosis
Modality: Small Molecules

Overview

XTS002 is a small molecule inhibitor of Voltage-dependent anion channel 1 (VDAC1) oligomerization, currently in preclinical development by X-tosis for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease. VDAC1 is a mitochondrial gatekeeper protein that, under pathological conditions, undergoes oligomerization, leading to mitochondrial dysfunction and the initiation of apoptosis. By preventing this oligomerization, XTS002 aims to restore mitochondrial function and protect neurons from degeneration. The program is currently in the IND-enabling phase of development.

Targets

VDAC1 (Hexokinase 2–voltage-dependent anion channel 1 complex)

Beyond the preview

Go deeper on XTS002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XTS002.

Explore the full profile